WALTHAM, Mass., June 20, 2025 - Zenas BioPharma Inc. (Nasdaq: ZBIO), a global biopharmaceutical company focused on autoimmune disease therapies, has announced a new stock option grant for a newly hired employee. On June 16, 2025, the company's Compensation Committee approved a non-qualified stock option to purchase 112,000 shares of Zenas' common stock as an inducement material for the employee's entry into the company. The stock option, priced at $9.97 per share, the closing price on the grant date, has a ten-year term. Vesting of the stock options will occur over four years, with 25% vesting on the first anniversary of employment and the remainder vesting in 36 equal monthly installments, contingent on continued employment with Zenas. This grant aligns with Nasdaq Listing Rule 5635(c)(4) and is governed by an Inducement Option Award Agreement.